Publication | Open Access
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
123
Citations
26
References
2022
Year
OncologyHepatologyMedicinePathologyBevacizumab Versus LenvatinibLiver CancerCancer TreatmentPharmacologyRadiation OncologyUnresectable Hepatocellular CarcinomaHepatocellular Carcinoma
| Year | Citations | |
|---|---|---|
Page 1
Page 1